EQ

-- -- --

From December 31, 2022 to December 31, 2023 Issuance of common stock for Bioniz acquisition Issuance of common stock under employee stock purchase plan Common stock repurchased

From June 30, 2023 to September 30, 2023 Common stock repurchased Issuance of common stock for Bioniz acquisition

From March 31, 2023 to June 30, 2023 Issuance of common stock under employee stock purchase plan

From December 31, 2021 to December 31, 2022 Issuance of common stock for Bioniz acquisition Issuance of common stock under employee stock purchase plan

From March 31, 2022 to June 30, 2022 Issuance of common stock under employee stock purchase plan

From December 31, 2020 to December 31, 2021 Issuance of common stock under registered direct offering, net of offering costs Exercise of stock options Issuance of common stock under employee stock purchase plan

From March 31, 2021 to June 30, 2021 Issuance of common stock under employee stock purchase plan Exercise of stock options

From December 31, 2020 To March 19, 2021 Issuance of common stock under registered direct offering, net of offering costs Exercise of stock options

1.Securities the company is offering: 4,285,710 Units, each Unit consisting of one share of Common Stock. 2.The number of shares of common stock to be outstanding immediately after this offering, as set forth in the table above, is based on 24,753,802 shares outstanding as of February 3, 2021.

from December 31, 2019 to December 31, 2020 Issuance of common stock from follow-on offering, net of issuance costs Issuance of common stock under ATM, net of issuance costs Issuance of common stock Issuance of common stock under employee stock purchase plan Exercise of stock options

From June 30, 2020 to September 30, 2020 Issuance of common stock, net of issuance costs Issuance of common stock under ATM, net of issuance costs

1.Securities the company is offering: 5,000,000 shares of common stock, par value $0.0001 per share. 2.The number of shares of common stock to be outstanding immediately after this offering, as set forth in the table above, is based on 19,263,375 shares outstanding as of August 13, 2020.

From March 31, 2020 to June 30, 2020 Issuance of common stock pursuant to employee stock purchase plan

From December 31, 2019 to March 31, 2020 Issuance of common stock under ATM facility,net of issuance costs Issuance of common stock

From December 31, 2018 to December 31, 2019 Issuance of common stock under ATM, net of issuance costs Issuance of common stock pursuant to employee stock purchase plan Exercise of stock options

from December 31, 2017 to November 13, 2018 Issuance of common stock, net of liability Issuance of common stock upon conversion of promissory notes Issuance of common stock to Biocon pursuant to certain anti-dilution rights Shares issued for public offering, net of underwriters’ fees and $2,123,106 of offering costs

1.Common stock offered 4,670,000 shares 2.The number of shares of our common stock to be outstanding after this offering is based on 12,082,658 shares of common stock outstanding as of June 30, 2018, including 267,690 shares of restricted common stock which are subject to a right of repurchase by us as of June 30, 2018 and after giving effect to (i) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 878,834 shares of our common stock based on the initial public offering price of $14.00 per share, and assuming the occurrence of the conversion on October 16, 2018 and (ii) the issuance by us of 228,060 shares of common stock upon completion of this offering to Biocon, pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on the initial public offering price of $14.00 per share